ArticleRegenerative biomaterials2026
Functional recovery after spinal cord injury through neuroprotection by lipoic acid-loaded hollow mesoporous Prussian blue nanozymes.
Article in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The key obstacle to functional recovery after spinal cord injury (SCI) is the imbalance of the oxidative stress microenvironment in the injured area. Traditional drug therapies have limitations in regulating this environment and eliminating the excessive accumulation of reactive oxygen species (ROS) is crucial. In this study, an environmentally friendly and economical recombinant nanoenzyme (LA-HMPB) was successfully constructed, which achieves delivery to the SCI injury site and enhances the therapeutic capacity of lipoic acid (LA). This nanoenzyme alleviates oxidative stress through the Keap1/Nrf2 pathway, thereby promoting functional recovery after SCI. The research found that HMPB not only serves as a carrier but also enhances the antioxidant stress capacity of LA. After administration, LA-HMPB can distribute to the SCI site and exert its effects. It has been confirmed that this formulation reduces oxidative stress levels by regulating the Keap1/Nrf2 pathway, thereby promoting functional recovery. This natural nano-drug delivery platform strategy opens up broad prospects for the clinical treatment of SCI and provides a useful reference for the research on antioxidant therapy for other neurological diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.